HedgePath Pharmaceuticals (HPPI) & Exelixis (EXEL) Critical Analysis

HedgePath Pharmaceuticals (OTCMKTS:HPPI) and Exelixis (NASDAQ:EXEL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and target prices for HedgePath Pharmaceuticals and Exelixis, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HedgePath Pharmaceuticals 0 0 0 0 N/A
Exelixis 1 2 8 0 2.64



Exelixis has a consensus price target of $30.38, suggesting a potential upside of 122.53%. Given Exelixis’ higher probable upside, analysts plainly believe Exelixis is more favorable than HedgePath Pharmaceuticals.

Risk & Volatility

HedgePath Pharmaceuticals has a beta of -6.39, indicating that its share price is 739% less volatile than the S&P 500. Comparatively, Exelixis has a beta of 1.94, indicating that its share price is 94% more volatile than the S&P 500.

Profitability

This table compares HedgePath Pharmaceuticals and Exelixis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
HedgePath Pharmaceuticals N/A -1,322.60% -279.15%
Exelixis 48.17% 65.68% 43.81%

Institutional and Insider Ownership

80.9% of Exelixis shares are owned by institutional investors. 4.3% of HedgePath Pharmaceuticals shares are owned by insiders. Comparatively, 4.8% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares HedgePath Pharmaceuticals and Exelixis’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
HedgePath Pharmaceuticals N/A N/A -$5.10 million N/A N/A
Exelixis $452.48 million 8.99 $154.22 million $0.51 26.76

Exelixis has higher revenue and earnings than HedgePath Pharmaceuticals.

Summary

Exelixis beats HedgePath Pharmaceuticals on 10 of the 10 factors compared between the two stocks.

About HedgePath Pharmaceuticals

HedgePath Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for patients with cancers in the United States. It primarily focuses on the development of therapies for skin, lung, and prostate cancers. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including stem cell maintenance, cell differentiation, tissue polarity, and cell proliferation. It is conducting an open-label Phase II (b) clinical trial for studying the effect of SUBA-Itraconazole oral capsules in patients with basal cell carcinoma nevus syndrome. SUBA-Itraconazole is a patented and proprietary itraconazole formulation that enhances the absorption of itraconazole to enhance the bioavailability of orally administered drugs that are poorly soluble. The company was founded in 1992 and is headquartered in Tampa, Florida.

About Exelixis

Exelixis, Inc., a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. It also offers COTELLIC tablets, an inhibitor of MEK in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, Daiichi Sankyo Company Limited, and Invenra, Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

Receive News & Ratings for HedgePath Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HedgePath Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply